pri-miR-34b/c

Association between polymorphisms in the promoter region of pri-miR-34b/c and risk of hepatocellular carcinoma

L. L. Chen, Shen, Y., Zhang, J. B., Wang, S., Jiang, T., Zheng, M. Q., Zheng, Z. J., Chen, C. X., Chen, L. L., Shen, Y., Zhang, J. B., Wang, S., Jiang, T., Zheng, M. Q., Zheng, Z. J., and Chen, C. X., “Association between polymorphisms in the promoter region of pri-miR-34b/c and risk of hepatocellular carcinoma”, vol. 15, p. -, 2016.

Hepatocellular carcinoma (HCC) is a major cause of cancer-related deaths worldwide. MicroRNA-34 (miR-34) gene plays a key role in altering the apoptotic cycle and pathways of downstream cells, and therefore influences carcinogenesis. In this case-control study, we assessed the role of the pri-miR-34b/c rs4938723 polymorphism in HCC risk. The pri-miR-34b/c polymorphic genotype was determined in 286 patients with HCC and 572 controls using polymerase chain reaction-restriction fragment length polymorphism.

Single-nucleotide polymorphism of the pri-miR-34b/c gene is not associated with susceptibility to congenital heart disease in the Han Chinese population

Y. - M. Liu, Wang, Y., Peng, W., Wu, Z., Wang, X. - H., Wang, M. - L., Wang, W., Sun, J., Zhang, Z. - D., and Mo, X. - M., “Single-nucleotide polymorphism of the pri-miR-34b/c gene is not associated with susceptibility to congenital heart disease in the Han Chinese population”, vol. 12, pp. 2937-2944, 2013.

Recent evidence has shown that the microRNA polymorphism may play an important role in the susceptibility to congenital heart disease (CHD). A potentially functional SNP rs4938723 (T>C) in the promoter region of pri-miR-34b/c might affect transcription factor GATA binding and therefore pri-miR-34b/c expression. We genotyped the pri-miR-34b/c polymorphism in a case-control study of 590 patients and 672 controls in a Han Chinese population and assessed the effects of the pri-miR-34b/c polymorphism on CHD susceptibility by TaqMan SNP genotyping assay.

Subscribe to pri-miR-34b/c